PI3K : a potential therapeutic target for cancer
Copyright © 2011 Wiley Periodicals, Inc..
Phosphatidylinositol 3-kinase (PI3K), one member of lipid kinase family, has been demonstrated to play a key role in regulating cell proliferation, adhesion, survival, and motility. Recent studies indicate that PI3K related signaling pathway is one of the most commonly activated pathways in human cancers. Accordingly, pharmacological inhibition of key nodes in this signaling cascade has been a focus in developmental therapeutics. To date, Inhibitors targeting PI3K or nodes in this pathway, AKT and mTOR, are best studied and have reached clinical trials. In this review, we will focus on recent progress on understanding of PI3Ks signaling pathway and the development of PI3K inhibitors.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2012 |
|---|---|
| Erschienen: |
2012 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:227 |
|---|---|
| Enthalten in: |
Journal of cellular physiology - 227(2012), 7 vom: 21. Juli, Seite 2818-21 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chen, Yingwei [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
EC 2.7.1.137 |
|---|
| Anmerkungen: |
Date Completed 19.07.2012 Date Revised 30.03.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1002/jcp.23038 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM211669466 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM211669466 | ||
| 003 | DE-627 | ||
| 005 | 20231224014032.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2012 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/jcp.23038 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0705.xml |
| 035 | |a (DE-627)NLM211669466 | ||
| 035 | |a (NLM)21938729 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chen, Yingwei |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a PI3K |b a potential therapeutic target for cancer |
| 264 | 1 | |c 2012 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.07.2012 | ||
| 500 | |a Date Revised 30.03.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2011 Wiley Periodicals, Inc. | ||
| 520 | |a Phosphatidylinositol 3-kinase (PI3K), one member of lipid kinase family, has been demonstrated to play a key role in regulating cell proliferation, adhesion, survival, and motility. Recent studies indicate that PI3K related signaling pathway is one of the most commonly activated pathways in human cancers. Accordingly, pharmacological inhibition of key nodes in this signaling cascade has been a focus in developmental therapeutics. To date, Inhibitors targeting PI3K or nodes in this pathway, AKT and mTOR, are best studied and have reached clinical trials. In this review, we will focus on recent progress on understanding of PI3Ks signaling pathway and the development of PI3K inhibitors | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Phosphoinositide-3 Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a Phosphatidylinositol 3-Kinase |2 NLM | |
| 650 | 7 | |a EC 2.7.1.137 |2 NLM | |
| 700 | 1 | |a Wang, Bao-Can |e verfasserin |4 aut | |
| 700 | 1 | |a Xiao, Yongtao |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of cellular physiology |d 1965 |g 227(2012), 7 vom: 21. Juli, Seite 2818-21 |w (DE-627)NLM000005304 |x 1097-4652 |7 nnns |
| 773 | 1 | 8 | |g volume:227 |g year:2012 |g number:7 |g day:21 |g month:07 |g pages:2818-21 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/jcp.23038 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 227 |j 2012 |e 7 |b 21 |c 07 |h 2818-21 | ||